HanesBrands (HBI) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 Good day and thank you for standing by. Welcome to the Hanesbrands First Quarter twenty twenty five Earnings Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you'll need to press 11 on your telephone. Please be advised that today's conference is being recorded. I would now like to hand the conference over ...

Identiv (INVE) Q1 2025 Earnings Call May 07, 2025 05:00 PM ET Company Participants Kirsten Newquist - CEOJustin Scarpulla - CFOStacy Che - Senior Associate Conference Call Participants Rian Bisson - Equity Research AnalystJaeson Schmidt - Director of Research - Senior Research Analyst Operator Good afternoon. Welcome to Identiv's presentation of its first quarter two thousand twenty five earnings call. My name is Tom, and I will be your operator this afternoon. Joining us for today's presentation are the co ...

Core Viewpoint - Teva Pharmaceutical's shares are experiencing a significant increase following the release of strong Q1 earnings and an upward revision of its full-year profit guidance [1][5]. Financial Performance - Teva reported Q1 adjusted earnings per share (EPS) of $0.52, surpassing Wall Street's expectation of $0.48 [2]. - The company reported quarterly sales of $3.89 billion, missing the anticipated $4 billion [2]. - Despite the revenue miss, Teva's margins expanded to 48.2%, up from 46.4% a year ago, attributed to a higher proportion of specialty drugs in overall sales [2]. Product Performance - The drug Austedo, used for treating movement disorders, generated worldwide revenue of $411 million for the quarter, reflecting a 39% increase compared to the same period last year [3]. Guidance Update - Teva raised its fiscal 2025 adjusted EPS guidance from a range of $2.35 to $2.65 to a new range of $2.45 to $2.65, with the new midpoint exceeding the consensus estimate of $2.55 [5]. Strategic Direction - CEO Richard Francis highlighted that Teva is entering the "Acceleration Phase" of its "Pivot to Growth Strategy," focusing on innovative growth, strengthening its generics business, and optimizing operations [6]. - The company's growth plan appears to be resonating well with investors, supported by efficiency measures and product growth [6][7].

Gildan Activewear Inc. (GIL) has shown an outstanding 44.8% surge in its stock price over the past year. The stock has outperformed the broader Consumer Discretionary sector and the S&P 500, which posted increases of 12.6% and 9.7%, respectively. Meanwhile, the Zacks Textile - Apparel industry, in which the company operates, has fallen 15.4% in the same time frame.The company is benefiting from its Sustainable Growth strategy, which aims at delivering organic top and bottom-line growth via capacity expansio ...

Core Viewpoint - Teva Pharmaceutical Industries Ltd reported its Q1 2025 financial results, showing a revenue increase but missing analyst expectations, while also providing an optimistic outlook for future earnings and operational efficiency [1][3][4]. Financial Performance - Teva's revenue for Q1 2025 was $3.89 billion, a 5% increase year-over-year, but below the analyst estimate of $4.00 billion [1]. - Adjusted earnings per share were 52 cents, surpassing estimates of 48 cents [3]. - Gross profit margin improved to 48.2% from 46.4% year-over-year, with adjusted gross profit margin rising to 52.8% from 51.4% [3]. Product Performance - Austedo's worldwide revenues reached $411 million in Q1 2025, marking a 39% increase in local currency compared to Q1 2024, with U.S. revenues growing by 40% to $396 million [1]. - Ajovy's global revenues were $139 million, a 26% increase in local currency terms compared to Q1 2024 [2]. - Uzedy's global revenues were $39 million in Q1 2025 [6]. Guidance and Outlook - Teva raised its fiscal 2025 adjusted earnings per share guidance from $2.35-$2.65 to $2.45-$2.65, aligning closely with the consensus of $2.55 [3][4]. - The company narrowed its 2025 sales guidance from $16.8 billion-$17.4 billion to $16.8 billion-$17.2 billion, compared to the consensus of $17.24 billion [4]. - Teva increased its Austedo 2025 sales outlook from approximately $1.9-2.05 billion to $1.95-2.05 billion [4]. Operational Strategy - Teva's CEO highlighted the company's transition into the "Acceleration Phase" of its Pivot to Growth Strategy, aiming for a 30% operating margin and $700 million in net savings by 2027 [3]. - The generics business showed growth across all regions, with a 5% increase in the U.S., 1% in Europe, and 2% in International Markets, all in local currency terms compared to Q1 2024 [6].

Teva Pharmaceutical Industries (TEVA) Q1 2025 Earnings Call May 07, 2025 08:00 AM ET Speaker0 Hello, and welcome to the Q1 twenty twenty five Teva Pharmaceutical Industries Limited Earnings Conference Call. My name is Alex, and I'll be coordinating the call today. I'll now hand it over to your host, Christopher Stivo, Head of Investor Relations to begin. Please go ahead. Speaker1 Thank you, Alex. Good morning, everyone. In the course of this call, we're going to be making some forward looking statements. An ...

May 7, 2025 Teva Pharmaceutical Industries Ltd. This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. These forward-looking statements ...

For an accessible version of this Press Release, please visit www.tevapharm.com Q1 2025 Highlights: (1) Revised 2025 outlook now includes no contribution from the Japan BV after Q1 and continues to include a full year contribution from Teva API, as well as exclude the expected income from development milestone payments from Sanofi in connection with the Phase 3 ulcerative colitis and Crohn's Disease initiations for duvakitug. (2) This outlook is based on the existing tariff and trade environment as of May 7 ...

LTC Properties (LTC) Q1 2025 Earnings Call May 06, 2025 11:00 AM ET Speaker0 ladies and gentlemen, and welcome to the LTC Properties Incorporated First Quarter twenty twenty five Earnings Call. At this time, all participants are on a listen only mode and a question and answer session will follow the formal presentation. Before management begins its presentation, please note that today's comments, including the question and answer session, may include forward looking statements subject to risks and uncertain ...

First Watch Restaurant Group (FWRG) Q1 2025 Earnings Call May 06, 2025 08:00 AM ET Company Participants Steven Marotta - VP of IRChristopher Tomasso - CEO, President & DirectorMel Hope - CFOAndrew Charles - Managing DirectorBrian Vaccaro - Managing Director - Equity ResearchAndy Barish - Managing DirectorMatt Eisenacher - Chief Brand OfficerPatrick Johnson - Equity Research Associate Conference Call Participants Jim Salera - Research AnalystJeffrey Bernstein - AnalystSara Senatore - AnalystJon Tower - Analy ...